SABCS 2022 | The association between JNK activity and immunotherapeutic efficacy of IO in TNBC

Naoto T. Ueno, MD, PhD, University of Hawaii, Honolulu, HI, discusses immunotherapy (IO) in triple negative breast cancer (TNBC) and the effects of JNK activity on IO. The biological changes following treatment with immunotherapy is currently unknown, particularly with checkpoint inhibitors (CPI) combined with chemotherapy. Exploring the biological changes could lead to superior combinations or de-escalation of treatment. Investigations into understanding inflammatory changes in TNBC and the impact on IO demonstrated high JNK activity to be associated with increased immunosuppression, decreasing the efficacy of CPIs. Research is currently underway to identify patients who will benefit from IO and whether the immunosuppressive activity of JNK can be reversed to enhance the efficacy of IO. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.